Glucagon-like peptide-1 receptor (GLP-1R)
The glucagon-like peptide-1 (GLP-1) receptor (GLP-1R), encoded by GLP1R, is a class B G protein-coupled receptor expressed in pancreatic β-cells, the gastrointestinal tract, heart, kidney and select regions of the central nervous system.
The glucagon-like peptide-1 (GLP-1) receptor (GLP-1R), encoded by GLP1R, is a class B G protein-coupled receptor expressed in pancreatic β-cells, the gastrointestinal tract, heart, kidney and select regions of the central nervous system. Its endogenous ligand, glucagon-like peptide-1 (GLP-1), is released by intestinal L-cells after a meal and degraded within minutes by Dipeptidyl peptidase 4 (DPP-4) — a half-life so short that every therapeutic agonist is built to evade that enzyme. Binding engages the two-domain mechanism typical of class B receptors, the peptide's C-terminus docking to the large extracellular domain while its N-terminus inserts into the transmembrane core, and couples through Gs to raise cyclic AMP. The downstream effectors, protein kinase A and the guanine nucleotide exchange factor Epac2, act on the β-cell's exocytotic machinery in a way that amplifies insulin release only when glucose is already elevated — the reason receptor agonists lower glucose without causing hypoglycemia on their own.
Through this pathway the receptor stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying and reduces food intake. Those effects have made it one of the most important drug targets of the past two decades: liraglutide, semaglutide and the dual GIP/GLP-1 co-agonist tirzepatide are in wide use for type 2 diabetes and obesity, and specific agents, in specific indications, reduce cardiovascular events and slow kidney disease progression. Which signals a given agonist favors, and how quickly the receptor internalizes after binding, differ between drugs and are now explicit design variables rather than incidental properties.
Outside the pancreas the receptor mediates gut-brain signaling, linking intestinal and hormonal cues to appetite, reward and mood circuitry, which underlies interest in addiction and neuropsychiatric indications. GLP-1R-targeted imaging is being investigated as a way to assess functional β-cell mass non-invasively, an approach that remains investigational rather than validated. Its roles in heart failure risk reduction, anticancer signaling and multi-target drug design continue to broaden the receptor's reach across disease areas.
Where the papers sit
37 papers from the last 6 months study Glucagon-like peptide-1 receptor (GLP-1R) directly · updated from PubMed 16 Nov 2026
Study type 6 clinical trials · 4 observational · 4 human data · 19 preclinical · 4 unclassified
Themes 5 themes · 1 paradigm shift · 1 new direction
-
Next-Generation Obesity Medicines
Obesity and type 2 diabetes treatment is moving toward oral GLP-1R agonists and unimolecular combinations that can reduce dependence on injections. Mazdutide, survodutide, elecoglipron, TERN-601 and zenagamtide are being judged mainly by weight loss, glycemic efficacy and adverse events. Small-molecule allosteric agonists and prodrug strategies aim to improve exposure and developability. Clinical durability, tolerability, delivery footprint and the balance between appetite suppression and aversion remain unresolved.
11 papers · 29.7%
-
Expanding GLP-1 Therapeutic Uses
GLP-1R agonists are being evaluated beyond glycemic control for heart failure with preserved ejection fraction, cardiovascular risk, stroke and neuroprotection. Genetic analyses and real-world cohorts repeatedly connect receptor activity with inflammation and improved cardiovascular outcomes, although causality and subgroup benefit remain unsettled. Peptide engineering, including stapled semaglutide scaffolds and receptor-guided PROTAC delivery, seeks more durable or selective action. Early work also tests GLP-1R with IL-17A in obesity-associated leukemia and with APJ in cardiorenal disease.
11 papers · 29.7%
-
GLP-1 and GIP Co-Agonism
GLP-1R and GIPR co-agonism is being extended with FGF21 trispecifics and other multi-target designs for obesity and glucose control. Exenatide and semaglutide work also recurs in longer-acting antibody-engaging or targeted delivery formats. β-cell survival, insulinotropic signaling and renal glucose transport are recurring mechanistic endpoints. Benefits remain mainly preclinical, and semaglutide or tirzepatide did not slow Alzheimer disease progression in 5xFAD mice.
8 papers · 21.6%
-
GLP-1 Therapies in MASH
MASH is the central target, with GLP-1R agonists and glucagon/GLP-1 or GLP-1/GIP combinations tested for steatosis, liver injury and steatohepatitis. DD01 and dulaglutide anchor therapeutic work, while dapagliflozin combinations address cardiometabolic control. Clinician knowledge of incretin therapies and coronary or blood-pressure effects broaden the clinical questions beyond liver histology. Tirzepatide PET imaging adds a way to quantify dual-receptor targeting, but comparative efficacy and long-term outcomes remain open.
5 papers · 13.5%
-
GLP-1 Beyond Metabolism
GLP-1R biology is extending from metabolic control into central circuits governing motivation and aversion. Septal GLP-1 receptors are linked to alcohol taking and seeking, while newer agonists such as zenagamtide frame broader behavioral and weight effects. The work remains early and heavily dependent on mechanistic and rodent evidence. Whether these pathways can translate into anti-addiction treatment while preserving useful metabolic effects remains open.
2 papers · 5.4%
GLP-1R agonism is not a unitary pathway but depends on ligand, receptor context, and neural circuit
The dorsal vagal complex circuit studied in GLP-1RA-induced feeding suppression and the GLP-1R/GIPR signaling system studied with GLP-1, semaglutide, and exendin-4 both challenge the assumption that GLP-1R agonists produce a common downstream response. In mice, NTS GLP-1R neurons regulated physiological feeding but did not mediate drug-induced weight loss, whereas AP GLP-1R neurons mediated both anorectic and aversive effects, placing those effects in the same circuit rather than in separable satiation and aversion pathways 42742987Sep. In human pancreatic islets and receptor-expression systems, different GLP-1R agonists produced distinct heterodimerization and phosphorylation patterns, while GIPR expression altered GLP-1R signaling, showing that receptor composition and ligand identity reshape the response 42419304Jul. GLP-1R pharmacology therefore requires attention to the particular agonist, cellular receptor context, and circuit rather than treating receptor activation as a uniform mechanism.
GLP-1R can serve as a receptor-guided intracellular delivery route for targeted protein degradation
A multicomponent stapled GLP-1 analogue linked to a BRD4-directed PROTAC used GLP-1R-positive cells as a selective entry route for a degrader payload, retaining receptor agonism while inducing selective intracellular BRD4 degradation 42283322Jun. This assigns GLP-1R a role beyond mediating metabolic pharmacology: it becomes a targeting and delivery handle for cell-selective proteolysis.
Papers
The 37 papers from the last 6 months that study Glucagon-like peptide-1 receptor (GLP-1R) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Next-Generation Obesity Medicines (11)
- Pharmacy students' knowledge and attitudes regarding GLP-1 receptor agonist adverse effects in obesity management: a cross-sectional study. The Libyan journal of medicine · 16 Oct 2026 PMID 42886550
- Estimating the carbon footprint of oral semaglutide (Rybelsus): a comparative analysis of the medicine carbon footprint model and manufacturer life-cycle assessment in pharmaceutical production. BMJ open · 24 Sept 2026 PMID 42785932
- A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists. The Journal of clinical investigation · 15 Sept 2026 PMID 42742987
- Design, synthesis, and biological activity of novel oxazole-based small molecule allosteric GLP-1R agonists. European journal of medicinal chemistry · 8 Aug 2026 PMID 42570411
- Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet (London, England) · 30 Jul 2026 PMID 42532080
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet (London, England) · 30 Jul 2026 PMID 42532079
- Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies. Obesity (Silver Spring, Md.) · 30 Jul 2026 PMID 42528333
- Lead-guided prodrug development of small molecules as GLP-1R agonists. Bioorganic chemistry · 9 Jul 2026 PMID 42424921
- Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet (London, England) · 8 Jun 2026 PMID 42259337
- Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England journal of medicine · 8 Jun 2026 PMID 42253238
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA · 7 Jun 2026 PMID 42251595
Expanding GLP-1 Therapeutic Uses (11)
- Glucagon-Like Peptide-1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association · 30 Oct 2026 PMID 42960821
- Cardiovascular outcomes associated With GLP-1 and dual GLP-1/GIP receptor agonists in patients with type 2 diabetes and inflammatory bowel disease: A retrospective real-world cohort study. PloS one · 24 Sept 2026 PMID 42784582
- A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan. Obesity research & clinical practice · 15 Sept 2026 PMID 42744726
- Glucagon-like peptide-1 receptor activation, inflammation and heart failure: Insights from genetic analysis. Heart & lung : the journal of critical care · 11 Sept 2026 PMID 42727531
- Impact of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms: Study protocol for a multicentric cohort study. PloS one · 9 Sept 2026 PMID 42715243
- Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting. Journal of enzyme inhibition and medicinal chemistry · 11 Aug 2026 PMID 42578506
- Protective effects of ACF210, a dual GLP-1/APJ receptor agonist, against cardiovascular-kidney-metabolic syndrome induced by T2D. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 4 Jul 2026 PMID 42401045
- Targeting GLP-1R and IL-17A suppresses obesity-induced leukemia in an oncogenic PTPN11 mutation-driven model. The Journal of clinical investigation · 23 Jun 2026 PMID 42334870
- Oral GLP-1 receptor agonist promotes astrocyte-neuron lactate and lipid transfer with neuroprotective effects. Cell metabolism · 22 Jun 2026 PMID 42330959
- Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery. Angewandte Chemie (International ed. in English) · 12 Jun 2026 PMID 42283322
- GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study. International journal of cardiology · 27 May 2026 PMID 42203003
GLP-1 and GIP Co-Agonism (8)
- GHRH and GLP-1 receptor agonism promote human β-cell survival and improve glucose homeostasis in diabetic mice. Endocrinology · 30 Sept 2026 PMID 42811814
- GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways. Cell chemical biology · 8 Jul 2026 PMID 42419304
- Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease. Cell reports. Medicine · 7 Jul 2026 PMID 42413499
- The Preparation and Physicochemical Characterization of a Triple Synergistic Nanoplatform Designed for Targeted Subcutaneous Delivery of Sitagliptin with Potential for β-Cell Preservation. AAPS PharmSciTech · 2 Jul 2026 PMID 42393437
- A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 29 Jun 2026 PMID 42372355
- IgG Fc-Binding Motif-Conjugated Exendin-4: A Long-Acting Hypoglycemic Agent via Broad-Spectrum Antibody Engagement for Type 2 Diabetes Therapy. Bioconjugate chemistry · 30 May 2026 PMID 42216891
- Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism. American journal of physiology. Renal physiology · 29 May 2026 PMID 42213650
- Identification of a novel oral potential multiple agonist for obesity treatment: multi-target in silico study. Journal of computer-aided molecular design · 20 May 2026 PMID 42162325
GLP-1 Therapies in MASH (5)
- PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide. Molecular pharmaceutics · 2 Nov 2026 PMID 42969740
- US Healthcare Professionals' Management of MASH and Knowledge of GLP-1, GIP, and Glucagon Receptor Agonists. Clinical and translational gastroenterology · 6 Oct 2026 PMID 42837671
- Glucagon-like peptide-1 receptor agonist dulaglutide attenuates liver injury in metabolic dysfunction-associated steatotic liver disease with diabetic mice. European journal of pharmacology · 17 Aug 2026 PMID 42607855
- The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial. The lancet. Gastroenterology & hepatology · 21 Jul 2026 PMID 42480572
- Effects of dapagliflozin and dulaglutide on blood pressure and coronary flow in liver steatosis patients with type 2 diabetes. Journal of hypertension · 27 May 2026 PMID 42201656
GLP-1 Beyond Metabolism (2)
- Going Beyond GLP-1. Science (New York, N.Y.) · 5 Nov 2026 PMID 42986946
- Septal GLP-1 receptors control alcohol taking and seeking. Neuron · 1 Jul 2026 PMID 42385677
By study type
Clinical trials (6)
- Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet (London, England) · 30 Jul 2026 PMID 42532080
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet (London, England) · 30 Jul 2026 PMID 42532079
- Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies. Obesity (Silver Spring, Md.) · 30 Jul 2026 PMID 42528333
- Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet (London, England) · 8 Jun 2026 PMID 42259337
- Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England journal of medicine · 8 Jun 2026 PMID 42253238
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA · 7 Jun 2026 PMID 42251595
Observational studies and case reports (4)
- Pharmacy students' knowledge and attitudes regarding GLP-1 receptor agonist adverse effects in obesity management: a cross-sectional study. The Libyan journal of medicine · 16 Oct 2026 PMID 42886550
- Cardiovascular outcomes associated With GLP-1 and dual GLP-1/GIP receptor agonists in patients with type 2 diabetes and inflammatory bowel disease: A retrospective real-world cohort study. PloS one · 24 Sept 2026 PMID 42784582
- Impact of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms: Study protocol for a multicentric cohort study. PloS one · 9 Sept 2026 PMID 42715243
- GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study. International journal of cardiology · 27 May 2026 PMID 42203003
Human data, design not indexed (4)
- Estimating the carbon footprint of oral semaglutide (Rybelsus): a comparative analysis of the medicine carbon footprint model and manufacturer life-cycle assessment in pharmaceutical production. BMJ open · 24 Sept 2026 PMID 42785932
- Glucagon-like peptide-1 receptor activation, inflammation and heart failure: Insights from genetic analysis. Heart & lung : the journal of critical care · 11 Sept 2026 PMID 42727531
- Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery. Angewandte Chemie (International ed. in English) · 12 Jun 2026 PMID 42283322
- Effects of dapagliflozin and dulaglutide on blood pressure and coronary flow in liver steatosis patients with type 2 diabetes. Journal of hypertension · 27 May 2026 PMID 42201656
Preclinical: animal, cell and lab studies (19)
- Going Beyond GLP-1. Science (New York, N.Y.) · 5 Nov 2026 PMID 42986946
- PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide. Molecular pharmaceutics · 2 Nov 2026 PMID 42969740
- GHRH and GLP-1 receptor agonism promote human β-cell survival and improve glucose homeostasis in diabetic mice. Endocrinology · 30 Sept 2026 PMID 42811814
- A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists. The Journal of clinical investigation · 15 Sept 2026 PMID 42742987
- Glucagon-like peptide-1 receptor agonist dulaglutide attenuates liver injury in metabolic dysfunction-associated steatotic liver disease with diabetic mice. European journal of pharmacology · 17 Aug 2026 PMID 42607855
- Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting. Journal of enzyme inhibition and medicinal chemistry · 11 Aug 2026 PMID 42578506
- Design, synthesis, and biological activity of novel oxazole-based small molecule allosteric GLP-1R agonists. European journal of medicinal chemistry · 8 Aug 2026 PMID 42570411
- Lead-guided prodrug development of small molecules as GLP-1R agonists. Bioorganic chemistry · 9 Jul 2026 PMID 42424921
- GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways. Cell chemical biology · 8 Jul 2026 PMID 42419304
- Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease. Cell reports. Medicine · 7 Jul 2026 PMID 42413499
- Protective effects of ACF210, a dual GLP-1/APJ receptor agonist, against cardiovascular-kidney-metabolic syndrome induced by T2D. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 4 Jul 2026 PMID 42401045
- The Preparation and Physicochemical Characterization of a Triple Synergistic Nanoplatform Designed for Targeted Subcutaneous Delivery of Sitagliptin with Potential for β-Cell Preservation. AAPS PharmSciTech · 2 Jul 2026 PMID 42393437
- Septal GLP-1 receptors control alcohol taking and seeking. Neuron · 1 Jul 2026 PMID 42385677
- A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 29 Jun 2026 PMID 42372355
- Targeting GLP-1R and IL-17A suppresses obesity-induced leukemia in an oncogenic PTPN11 mutation-driven model. The Journal of clinical investigation · 23 Jun 2026 PMID 42334870
- Oral GLP-1 receptor agonist promotes astrocyte-neuron lactate and lipid transfer with neuroprotective effects. Cell metabolism · 22 Jun 2026 PMID 42330959
- IgG Fc-Binding Motif-Conjugated Exendin-4: A Long-Acting Hypoglycemic Agent via Broad-Spectrum Antibody Engagement for Type 2 Diabetes Therapy. Bioconjugate chemistry · 30 May 2026 PMID 42216891
- Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism. American journal of physiology. Renal physiology · 29 May 2026 PMID 42213650
- Identification of a novel oral potential multiple agonist for obesity treatment: multi-target in silico study. Journal of computer-aided molecular design · 20 May 2026 PMID 42162325
Unclassified: not yet indexed with MeSH (4)
- Glucagon-Like Peptide-1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association · 30 Oct 2026 PMID 42960821
- US Healthcare Professionals' Management of MASH and Knowledge of GLP-1, GIP, and Glucagon Receptor Agonists. Clinical and translational gastroenterology · 6 Oct 2026 PMID 42837671
- A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan. Obesity research & clinical practice · 15 Sept 2026 PMID 42744726
- The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial. The lancet. Gastroenterology & hepatology · 21 Jul 2026 PMID 42480572
Written from 37 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-26 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.